Abdallah Rayyan

IM PGY2 @ucf @UCFGNVIM | Aspiring Cardiologist🫀

[Abdallah Rayyan @abdrayyan98]

Excited to share our latest publication in JACC: Case Reports on a stent-sparing approach for recurrent coronary restenosis in Takayasu arteritis.

#Cardiology #JACC @JACCJournals

https://t.co/BlifgRfgRB

[Abdallah Rayyan @abdrayyan98]

A few incredible days at #CCCES26. Deep dives on bleeding & coagulopathy in the CICU, cardiogenic shock, PE, plus hands-on skills.
Happy to have met colleagues and educators interested in this field.
Thank you @AndreaElliottUM and @UMN_CCCEdSummit for an outstanding summit. 🫀

[Laith Alhuneafat @LAlhuneafat]

Great start to the day with some tMCS troubleshooting!

#CCCES2026

[Abdallah Rayyan @abdrayyan98]

Just completed the ACGME Leadership Training Program for Chief Residents in Chicago. Great few days learning about leadership, communication, wellness, and program improvement alongside chiefs from across the country. Grateful for the opportunity and excited for the upcoming year

[Abdallah Rayyan @abdrayyan98]

@enad1998 Congratulations Enad!🎉

[Hassan Kawtharany, MD, MSCI @Hassankwth]

Deep dive into atrial fibrillation after hematopoietic stem cell transplant #AFib #HSCT #BMT #EPeeps
https://t.co/W7qCCUmZCf

[Abdallah Rayyan @abdrayyan98]

Excited to share our new review on atrial fibrillation after hematopoietic stem cell transplant.

We highlight incidence, risk factors, management challenges, and the need for HSCT-specific AF risk tools.
@Hassankwth @Mhamad8azal
https://t.co/OoLFvGBSeY

[Abdallah Rayyan @abdrayyan98]

MCS selection should not be driven by trial headlines alone. Understanding the differences between RCT populations and the patient in front of you is key to choosing the right platform.

[Abdallah Rayyan @abdrayyan98]

Great first day of the Annual Critical Care Cardiology Virtual Summit!

Excellent educational sessions and a fantastic debate on norepinephrine vs epinephrine in cardiogenic shock. Looking forward to the upcoming sessions!
#CriticalCareCardiology #CardiogenicShock

[Abdallah Rayyan @abdrayyan98]

Etiology matters. The SHARC framework helps phenotype CS into AMI-CS, HF-CS, secondary CS from non-myocardial causes such as VT, valvular or pericardial disease, and post-cardiotomy CS.

[Abdallah Rayyan @abdrayyan98]

@BsherAlmaalouli Congratulations Bsher, strong work as always!!

[Abdallah Rayyan @abdrayyan98]

Grateful and humbled to have won the case presentation session.

Thank you to Dr. Velarde for leading such an excellent symposium, truly a great experience and learned alot from the outstanding presenters 🙏 @ggvela

[UF Jacksonville Cardiology Fellowship @ufjaxcards]

Congrats to Dr. Abdallah Rayyan on winning the case presentation session at the Women’s Cardiovascular Disease Symposium!
Outstanding work on a complex ISR case in Takayasu arteritis 👏
@ggvela
#WomensHeartHealth #CardioTwitter #Cardiology #MedEd

[Abdallah Rayyan @abdrayyan98]

@AbdullahAlabcha @MayoClinicCV @MayoCVFellows @ACCmediacenter @ACCinTouch @AASC_Cardiology Congratulations!

[Abdallah Rayyan @abdrayyan98]

Great experience presenting at @ACCinTouch!

Incredible science, meaningful discussions, and always great catching up with friends and colleagues. Grateful to be part of such an inspiring community.

#ACC26

[Abdallah Rayyan @abdrayyan98]

@AlimoradiMD Great seeing you always!

[Abdallah Rayyan @abdrayyan98]

@LAlhuneafat Thank you so much for your help!

[Abdallah Rayyan @abdrayyan98]

Excited to be at @ACCinTouch!

Join me tomorrow as I present our work on the AST/ALT ratio as a simple, early predictor of mortality and renal failure in cardiogenic shock.

🗓️ March 29 | ⏰ 11:00 AM
#ACC26

[Abdallah Rayyan @abdrayyan98]

Check our latest study showing that in MI patients with LVEF >40%:
• No mortality benefit with β-blockers
• No ↓ arrhythmia or revascularization
• Signal toward ↓recurrent MI
• Signal toward ↓new HF

https://t.co/b3xI8Ol2WC
@Hassankwth @alichoaibb @hamarshaqa @MuayadAzzam

[Abdallah Rayyan @abdrayyan98]

Sharing our work in Heart Rhythm O2 comparing catheter ablation vs antiarrhythmic drugs in patients with HCM and persistent atrial fibrillation:

• Lower 12-months mortality and better survival
• Fewer CHF exacerbations & hospitalizations

[Nashwa Abdulsalam @Nashwa_Salem_]

👀 What’s the best rhythm strategy in HCM with persistent AF?

Published in @HRS_O2Journal this study shows catheter ablation is superior to AADs:
✨ Lower 12-mo mortality
✨ Fewer CHF exacerbation & hospitalizations
✨ Better survival (98.8% vs 96.5%)
#EPeeps